GSK and Moderna settle patent dispute over COVID‑19 and RSV vaccine technology
British drugmaker GSK and U.S. vaccine developer Moderna ended their litigation in the United States and Europe by signing a cross‑licensing agreement. The settlement, finalized on October 28, covers Moderna’s COVID‑19 shots Spikevax and mNEXSPIKE and its RSV vaccine mResvia, and requires no monetary payments from either side. Both firms asked a Delaware federal court to permanently dismiss GSK’s U.S. patent claims, removing the dispute from the courts.
Why it matters
GSK said the resolution removes legal uncertainty and lets both companies concentrate on advancing vaccine innovation. The removal of the lawsuit also eliminates future legal costs and potential damages for the parties.
Key facts
- 1The settlement covers Moderna’s COVID‑19 vaccines Spikevax and mNEXSPIKE, as well as its RSV vaccine mResvia. finance.yahoo.com
- 2The agreement was reached on October 28. finance.yahoo.com
- 3Both companies will cross‑license each other’s patented technology and no payments are required. finance.yahoo.com
- 4GSK and Moderna asked a federal court in Delaware to permanently dismiss GSK’s U.S. patent infringement claims. finance.yahoo.com
- 5GSK originally sued Moderna in 2024 over lipid‑nanoparticle technology used in the vaccines. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.